As of 30 Sep 2025, 229 institutional investors reported holding 102,790,896 shares of Summit Therapeutics Inc. - COM (SMMT).
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 1,282,044 | $22,446,744 | -$13,186,188 | $17.49 | 26 |
| 2025 Q3 | 102,790,896 | $2,124,232,954 | +$101,213,367 | $20.66 | 229 |
| 2025 Q2 | 97,848,320 | $2,079,803,739 | +$34,103,760 | $21.28 | 225 |
| 2025 Q1 | 97,733,829 | $1,887,229,460 | +$89,016,125 | $19.29 | 199 |
| 2024 Q4 | 92,601,649 | $1,651,990,072 | +$117,644,267 | $17.84 | 193 |
| 2024 Q3 | 84,449,125 | $1,847,583,748 | +$298,192,308 | $21.90 | 166 |
| 2024 Q2 | 72,161,219 | $562,868,531 | +$188,424,190 | $7.80 | 122 |
| 2024 Q1 | 49,052,391 | $203,075,979 | +$69,810,023 | $4.14 | 100 |
| 2023 Q4 | 60,902 | $158,954 | +$4,513 | $2.61 | 2 |
| 2023 Q3 | 32,297,340 | $60,396,159 | -$5,247,501 | $1.87 | 90 |
| 2023 Q2 | 34,903,696 | $87,606,021 | +$36,497,902 | $2.51 | 96 |
| 2023 Q1 | 21,131,959 | $36,976,249 | +$22,179,404 | $1.75 | 86 |
| 2022 Q4 | 8,001,933 | $34,005,890 | +$22,167,621 | $4.25 | 56 |
| 2022 Q3 | 3,173,874 | $3,774,379 | -$5,146,785 | $1.19 | 37 |
| 2022 Q2 | 8,452,115 | $8,451,000 | -$4,223,110 | $1.00 | 32 |
| 2022 Q1 | 10,619,952 | $26,021,000 | -$224,387 | $2.45 | 42 |
| 2021 Q4 | 10,675,809 | $28,715,000 | -$162,099 | $2.69 | 47 |
| 2021 Q3 | 10,720,423 | $53,813,617 | -$1,094,265 | $5.01 | 50 |
| 2021 Q2 | 11,040,017 | $82,356,721 | +$14,136,643 | $7.46 | 53 |
| 2021 Q1 | 9,283,184 | $54,489,348 | +$1,357,968 | $5.87 | 36 |
| 2020 Q4 | 8,511,704 | $40,004,259 | -$70,124 | $4.70 | 28 |
| 2020 Q3 | 7,749,022 | $26,749,440 | +$26,749,393 | $3.44 | 14 |